Treese Christoph, Sanchez Pedro, Grabowski Patricia, Berg Erika, Bläker Hendrik, Kruschewski Martin, Haase Oliver, Hummel Michael, Daum Severin
Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.
PLoS One. 2016 Dec 28;11(12):e0168237. doi: 10.1371/journal.pone.0168237. eCollection 2016.
5-year survival rate in patients with early adenocarcinoma of the gastro-esophageal junction or stomach (AGE/S) in Caucasian patients is reported to be 60-80%. We aimed to identify prognostic markers for patients with UICC-I without lymph-node involvement (N0).
Clinical data and tissue specimen from patients with AGE/S stage UICC-I-N0, treated by surgery only, were collected retrospectively. Tumor size, lymphatic vessel or vein invasion, grading, classification systems (WHO, Lauren, Ming), expression of BAX, BCL-2, CDX2, Cyclin E, E-cadherin, Ki-67, TP53, TP21, SHH, Survivin, HIF1A, TROP2 and mismatch repair deficiency were analyzed using tissue microarrays and correlated with overall and tumor related survival.
129 patients (48 female) with a mean follow-up of 129.1 months were identified. 5-year overall survival was 83.9%, 5-year tumor related survival was 95.1%. Poorly differentiated medullary cancer subtypes (p<0.001) and positive vein invasion (p<0.001) were identified as risk factors for decreased overall-and tumor related survival. Ki-67 (p = 0.012) and TP53 mutation (p = 0.044) were the only immunohistochemical markers associated with worse overall survival but did not reach significance for decreased tumor related survival.
In the presented study patients with AGE/S in stage UICC-I-N0 had a better prognosis as previously reported for Caucasian patients. Poorly differentiated medullary subtype was associated with reduced survival and should be considered when studying prognosis in these patients.
据报道,白种人胃食管交界或胃早期腺癌(AGE/S)患者的5年生存率为60%-80%。我们旨在确定国际抗癌联盟(UICC)-I期且无淋巴结转移(N0)患者的预后标志物。
回顾性收集仅接受手术治疗的UICC-I-N0期AGE/S患者的临床资料和组织标本。使用组织芯片分析肿瘤大小、淋巴管或静脉侵犯、分级、分类系统(世界卫生组织、劳伦、明氏)、BAX、BCL-2、CDX2、细胞周期蛋白E、E-钙黏蛋白、Ki-67、TP53、TP21、SHH、生存素、低氧诱导因子1α(HIF1A)、滋养层细胞表面抗原2(TROP2)的表达以及错配修复缺陷,并将其与总生存期和肿瘤相关生存期进行关联分析。
共纳入129例患者(48例女性),平均随访129.1个月。5年总生存率为83.9%,5年肿瘤相关生存率为95.1%。低分化髓样癌亚型(p<0.001)和静脉侵犯阳性(p<0.001)被确定为总生存期和肿瘤相关生存期降低的危险因素。Ki-67(p = 0.012)和TP53突变(p = 0.044)是仅有的与较差总生存期相关的免疫组化标志物,但对肿瘤相关生存期降低未达到显著水平。
在本研究中,UICC-I-N0期AGE/S患者的预后较先前报道的白种人患者更好。低分化髓样亚型与生存率降低相关,在研究这些患者的预后时应予以考虑。